Stockreport

Xencor Announces Extension of U.S. Patent Term on Certain Xtend™ Antibodies

Xencor, Inc.  (XNCR) 
Last xencor, inc. earnings: 2/24 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: investors.xencor.com/investor-relations
PDF -- Royalty term on Ultomiris® sales in the United States anticipated to continue into year-end 2028, extending term by three years ---- Additional $100 million to $120 m [Read more]